- $12.41m
- -$56.21m
- 20
- 55
- 27
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.19 | ||
| Price to Tang. Book | 0.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.81% | ||
| Return on Equity | -61.87% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.38 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Directors
- David Kabakoff NEC (73)
- Michael Richman PRE (60)
- Steven Cobourn CFO (58)
- Timothy Mayer COO (56)
- Linda Liu SVP (54)
- Sol Langermann CSO (61)
- Han Myint OTH (68)
- Anne Borgman IND
- Ellen Feigal IND (67)
- John Houston IND (61)
- Elaine Jones IND (66)
- Chau Khuong IND (45)
- Garry Nicholson IND (66)
- Stephen Webster IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 3rd, 2015
- Public Since
- May 9th, 2019
- No. of Shareholders
- 19
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 28,050,191
- Address
- 9000 Virginia Manor Rd Ste 200, BELTSVILLE, 20705-4214
- Web
- https://www.nextcure.com/
- Phone
- +1 2403994900
- Auditors
- Ernst & Young LLP
Upcoming Events for NXTC
NextCure Inc Annual Shareholders Meeting
Q2 2025 NextCure Inc Earnings Release
Similar to NXTC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the NextCure share price?
As of Today at 22:17 UTC, shares in NextCure are trading at $0.44. This share price information is delayed by 15 minutes.
How has the NextCure share price performed this year?
Shares in NextCure last closed at $0.44 and the price had moved by -70.3% over the past 365 days. In terms of relative price strength the NextCure share price has underperformed the S&P500 Index by -73.22% over the past year.
What are the analyst and broker recommendations for NextCure?
The overall consensus recommendation for NextCure is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the NextCure dividend yield?
NextCure does not currently pay a dividend.
Does NextCure pay a dividend?
NextCure does not currently pay a dividend.
When does NextCure next pay dividends?
NextCure does not currently pay a dividend.
How do I buy NextCure shares?
To buy shares in NextCure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NextCure?
As of the previous close price of $0.44, shares in NextCure had a market capitalisation of $12.41m.
Where are NextCure shares listed?
Here are the trading details for NextCure:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NXTC
What kind of share is NextCure?
Based on an overall assessment of its quality, value and momentum NextCure is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NextCure share price forecast for 2025?
The analyst consensus target price for shares in NextCure is $3.00. That is 577.97% above the last closing price of $0.44.
Analysts covering NextCure currently have a consensus Earnings Per Share (EPS) forecast of -$1.75 for the next financial year.
Find out moreWhat is the trend in the NextCure share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NextCure. Over the past six months, its share price has underperformed the S&P500 Index by -66.58%.
As of the last closing price of $0.44, shares in NextCure were trading -58.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NextCure PE Ratio?
The NextCure PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NextCure?
NextCure's management team is headed by:
- David Kabakoff - NEC
- Michael Richman - PRE
- Steven Cobourn - CFO
- Timothy Mayer - COO
- Linda Liu - SVP
- Sol Langermann - CSO
- Han Myint - OTH
- Anne Borgman - IND
- Ellen Feigal - IND
- John Houston - IND
- Elaine Jones - IND
- Chau Khuong - IND
- Garry Nicholson - IND
- Stephen Webster - IND